| Description : |
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. |
| Source : |
E. coli |
| Species : |
Human |
| Tag : |
His |
| Form : |
25mM Tris, pH8.0, 150 mM NaCl, 10% glycerol, 1 % Sarkosyl. |
| Molecular Mass : |
24 kDa |
| AA Sequence : |
A DNA sequence encoding human full-length VHL. |
| Purity : |
> 80% as determined by SDS-PAGE and Coomassie blue staining. |
| Stability : |
Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. |
| Storage : |
Store at -80 centigrade. |
| Concentration : |
>50 ug/mL as determined by microplate BCA method. |
| Protein Families : |
Druggable Genome, Transcription Factors |
| Protein Pathways : |
Pathways in cancer, Renal cell carcinoma, Ubiquitin mediated proteolysis |
